Technical Analysis for RXDX - Prometheus Biosciences, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | N/A | N/A | Up |
Historical RXDX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing High | Bullish | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Above Upper BB | Strength | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Up 3 Days in a Row | Strength | 0.00% | |
Up 4 Days in a Row | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
Stochastic Reached Overbought | Strength | 5.87% | |
Wide Bands | Range Expansion | 5.87% | |
Overbought Stochastic | Strength | 5.87% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time |
---|---|
Upper Bollinger Band Resistance | 1 day ago |
Rose Above Upper Bollinger Band | 1 day ago |
Up 3% | 1 day ago |
Up 2% | 1 day ago |
Rose Above Previous Day's High | 1 day ago |
Get a Trading Sidekick!
- Earnings date: ???
Prometheus Biosciences, Inc. Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of precision therapeutics and companion diagnostics products for the treatment and diagnosis of inflammatory bowel diseases (IBD). Its products include PRA023, a Phase I clinical trial IgG1 humanized monoclonal antibody (mAb); PR600, an anti- tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1800, anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. The company has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. Prometheus Biosciences, Inc. was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. The company was founded in 2016 and is based in San Diego, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Medicine Immunology Inflammatory Bowel Disease Tumor Necrosis Factor Inflammatory Bowel Diseases
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 28.33 |
52 Week Low | 16.11 |
Average Volume | 213,987 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 0.00 |
20-Day Moving Average | 20.67 |
10-Day Moving Average | 21.60 |
Average True Range | 2.63 |
ADX | 0.0 |
+DI | 24.98 |
-DI | 21.32 |
Chandelier Exit (Long, 3 ATRs ) | 20.43 |
Chandelier Exit (Short, 3 ATRs ) | 24.01 |
Upper Bollinger Band | 25.74 |
Lower Bollinger Band | 15.59 |
Percent B (%b) | 1.02 |
BandWidth | 49.14 |
MACD Line | 1.06 |
MACD Signal Line | 0.29 |
MACD Histogram | 0.7701 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 30.81 | ||||
Resistance 3 (R3) | 30.35 | 28.30 | 30.00 | ||
Resistance 2 (R2) | 28.30 | 27.07 | 28.52 | 29.73 | |
Resistance 1 (R1) | 27.14 | 26.31 | 27.72 | 27.60 | 29.47 |
Pivot Point | 25.09 | 25.09 | 25.38 | 25.31 | 25.09 |
Support 1 (S1) | 23.93 | 23.86 | 24.51 | 24.39 | 22.51 |
Support 2 (S2) | 21.88 | 23.10 | 22.10 | 22.25 | |
Support 3 (S3) | 20.72 | 21.88 | 21.98 | ||
Support 4 (S4) | 21.18 |